Livestock Nutrition Center made non-medicated animal feed contaminated with monensin, killing animals; FDA found preventive control failures.
What happened
FDA inspected the Garden City, KS feed mill from August 29 through September 17, 2024, after the company filed a Reportable Food Registry report about multiple animal deaths after animals ate LNC Pasture Gold 24-5 Plus lot #7153, made on August 20, 2024. FDA and the company's third-party lab analyzed feed from a customer and a retention sample and found monensin, a drug used in medicated cattle feed, in the non-medicated product even though it was not formulated or labeled to contain it. FDA said sample results and animal diagnostic findings indicate the animals died from monensin toxicity; the company recalled the product on August 26, 2024.
What FDA found
The Food Safety Plan did not identify and evaluate the known hazard of cross-contamination from an animal drug at the mixing stage.
21 CFR 507.33(c)(1)The company's prerequisite programs were inadequate to prevent drug carryover; after making LNC Rumensin 5 Pellet, it made non-medicated LNC Pasture Gold 24-5 Pellet in the same equipment, and monensin carried over.
21 CFR 507.1(a)(1)(ii); FD&C Act Section 402(a)(4)A customer sample of LNC Pasture Gold 24-5 Pellet contained monensin at 638 mg/kg to 2110 mg/kg; the drug was not used according to its approval, making the feed unsafe and adulterated.
FD&C Act Section 512(a)(2) [21 U.S.C. § 360b(a)(2)]; Section 402(a)(2)(C)(ii) [21 U.S.C. § 342(a)(2)(C)(ii)]
What FDA wants
Within 15 working days, tell FDA in writing what specific steps you have taken to correct the violations, explain how you will prevent recurrence, and include supporting documents. If you cannot finish within that time, state why and give a completion timeframe.
Who should pay attention
- feed mills that share mixing equipment between medicated and non-medicated products
- livestock producers and horse owners who buy non-medicated feed
- brands that rely on contract feed manufacturers
This is a summary. Read the original letter on fda.gov.